Pediatrix Medical Group, Inc.
NYSE:MDMedical - Care Facilities
-$0.48 today
- Market cap
- $2.41B
- Beta
- 0.70
- P/E (TTM)
- 11.0
- EPS (TTM)
- $2.10
Volume 0.64M
Average 0.82M
MD Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Pediatrix Medical Group, Inc.NYSE: MD
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development remains negative
Q3 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How MD compares with its peers on the latest reported figures
- MD's LTM Sep 2026 research & development of $0 is the 2nd highest of the 11 companies compared; the peer median is $0.
- Research & development amounts to 0.0% of revenue for MD, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $357M | -11.9% | -8.1% | 5.9% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
GRDNGuardian Pharmacy Services, Inc. | LTM Jun 2026 | $0 | — | — | 0.0% |
| LTM Oct 2026 | $0 | — | — | 0.0% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $0 | — | — | 0.0% |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding MD) | $0 | -11.9% | -8.1% | 0.0% | |
Competitors are the stored peer set for MD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.91B | 1.97B | 1.99B | 2.01B | 1.91B |
| Cost of Revenue | 1.4B | 1.5B | 1.57B | 1.56B | 1.44B |
| Gross Profit | 513.24M | 467.03M | 421.57M | 454.34M | 471.88M |
| Gross Margin | 26.9% | 23.7% | 21.1% | 22.6% | 24.7% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 263.36M | 231.4M | 227.54M | 238.44M | 240.79M |
| Operating Expenses | 310.32M | 294.35M | 414.24M | 523.06M | 240.79M |
| Depreciation & Amortization | 32.15M | 35.64M | 36.17M | 32.23M | 21.83M |
| EBITDA | 236.1M | 156.7M | 29.89M | (28.37M) | 274.22M |
| EBITDA Margin | 12.4% | 7.9% | 1.5% | -1.4% | 14.3% |
| Operating Income | 202.92M | 172.69M | 7.32M | (68.71M) | 231.09M |
| Operating Margin | 10.6% | 8.8% | 0.4% | -3.4% | 12.1% |
| Interest Income | 0 | 0 | 0 | 0 | 19.05M |
| Interest Expense | 68.72M | 39.7M | 42.08M | 40.74M | 35.97M |
| Other Income / Expenses | (67.69M) | (91.32M) | (55.68M) | (32.63M) | (14.65M) |
| Income Before Tax | 135.23M | 81.37M | (48.36M) | (101.34M) | 216.43M |
| Pre-Tax Margin | 7.1% | 4.1% | -2.4% | -5.0% | 11.3% |
| Income Tax Expense | 27.24M | 18.81M | 12.05M | (2.27M) | 51.04M |
| Net Income | 130.96M | 66.34M | (60.41M) | (99.07M) | 165.39M |
| Net Margin | 6.9% | 3.4% | -3.0% | -4.9% | 8.6% |
| EPS (Basic) | 1.52 | 0.80 | (0.73) | (1.19) | 1.94 |
| EPS (Diluted) | 1.52 | 0.79 | (0.73) | (1.19) | 1.94 |
| Weighted Avg Shares | 86.42M | 82.95M | 82.2M | 83.33M | 85.27M |
| Weighted Avg Shares (Diluted) | 86.42M | 84.12M | 82.2M | 83.33M | 85.27M |
Pediatrix Medical Group, Inc.
NYSE:MD
Intrinsic Alpha fair value
Locked
Current Price
$30.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.